Question Title

1. I am:

Patient-Related Factors

Question Title

2. How confident are you in identifying patient risk factors for invasive fungal infections (IFIs)?

Question Title

3. How would you typically treat a patient with persistent (>3 days) neutropenic fever?

Question Title

4. I am aware of when therapeutic drug monitoring (TDM) is needed for my patients on antifungal therapy.

Treatment-Related Strategies

Question Title

5. Does your institution utilize guidelines for the use of antifungal prophylaxis in high-risk patients?

Question Title

6. How often do you utilize IDSA guidelines when selecting antifungal treatment for patients with invasive candidiasis or aspergillosis?

Question Title

7. I frequently use combination antifungal therapy for (check all that apply):

System-Based Issues and Opportunities

Question Title

8. When invasive candidiasis is confirmed at your institution, how often is susceptibility testing performed?

Question Title

9. Approximately how long does it take to get susceptibility results from the clinical microbiology lab?

Question Title

10. At your institution, when an IFI is suspected, how much time typically passes before antifungal treatment is initiated?

Question Title

11. I feel that it is imperative to collaborate with the following clinicians when managing a patient with an IFI (check all that apply)

Thank you for taking the time to complete this survey.
( Privacy & Cookie Notice

T